BUZZ-Biohaven falls as genetic disorder drug fails to meet goal in late-stage study

Reuters11-25 21:26
BUZZ-Biohaven falls as genetic disorder drug fails to meet goal in late-stage study

** Shares of drug developer Biohaven Ltd BHVN.N fall 14.4% to $39.02 premarket

** BHVN says its experimental drug, taldefgrobep alfa, did not meet the main goal of improving muscle function in patients with a rare neuromuscular disorder called spinal muscular atrophy in a late-stage study

** Taldefgrobep alfa is designed to block myostatin, a protein that limits muscle growth, which helps increase muscle mass and improve muscle function

** However, the drug showed positive effects on body composition, such as reducing fat mass, supporting its potential as an obesity treatment, co says

** As of last close, stock has risen 6.5% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment